[{"indications": "Indications\u00a0opioid-induced constipation in terminally\r\nill patients, when response to other laxatives is inadequate", "name": "METHYLNALTREXONE BROMIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.6 Laxatives", "1.6.6 Peripheral opioid-receptor antagonists", "METHYLNALTREXONE BROMIDE"], "cautions": "Cautions\u00a0diverticular disease; faecal impaction; patients with colostomy or peritoneal catheter", "side-effects": "Side-effects\u00a0abdominal pain, nausea, diarrhoea, flatulence;\r\ndizziness; injection site reactions, hyperhidrosis; also reported\r\ngastro-intestinal perforation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201642.htm", "doses": ["By subcutaneous injection, adult over 18 years, body-weight under 38\u00a0kg, 150\u00a0micrograms/kg\r\non alternate days; body-weight 38\u201362\u00a0kg, 8\u00a0mg on alternate days; body-weight\r\n62\u2013114\u00a0kg, 12\u00a0mg on alternate days; body-weight over 114\u00a0kg, 150\u00a0micrograms/kg\r\non alternate days; may be given less frequently depending on response;\r\n2 consecutive doses may be given 24 hours apart if no response to\r\ntreatment on the preceding day; rotate sites of injection; max. duration\r\nof treatment 4 months", "May act within 30\u201360 minutes"], "pregnancy": "Pregnancy\u00a0toxicity at high doses in animal studies\u2014manufacturer advises avoid unless essential"}]